Testing VG2062 for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial is testing a new drug called VG2062 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how the body processes it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have an advanced solid tumor that did not respond to standard treatments and no other effective options are available.
- You have not taken any other experimental drugs or had major surgery in the last 4 weeks.
- You do not have an active herpes simplex infection (like cold sores or genital herpes) or other uncontrolled infections.
- You agree to use reliable birth control during the study and for 90 days after the last dose, if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, VG2025, given through a vein for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and if it can help shrink or control the tumors.
This Phase 1 trial tests the safety and early effects of VG2025 in people with advanced solid cancers that have stopped responding to standard treatments. It’s mainly looking for side effects and how the body processes the drug, and it may offer a new option when other treatments haven’t worked.
This trial tests a new virus-based therapy (VG161) injected directly into tumors for people with advanced bone and soft tissue sarcoma that hasn't responded to other treatments. The goal is to see if the virus can shrink tumors and slow the cancer's growth.
This early (Phase 1) study tests VG2025, given alone or with nivolumab, in people with advanced solid cancers that have not responded to standard treatment. It may help by activating an immune response against cancer, especially in people who have HSV (herpes simplex virus) in their system.
This trial tests a new medicine called VG161 for people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer) that has stopped responding to or could not be tolerated after at least one prior treatment. It is given by injection into the tumor, and the study wants to see if it can help shrink or control the cancer.
This trial tests a combination of two drugs, VG161 (a virus that targets cancer cells) and camrelizumab (an immunotherapy), for people with advanced liver cancer that has not responded to or stopped working after first-line treatment. It aims to see if this combination can shrink tumors and help patients live longer.
Hear when a new Advanced Malignant Solid Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.